ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …

Abstract Treatment options for COVID‐19, caused by SARS‐CoV‐2, remain limited.
Understanding viral pathogenesis at the molecular level is critical to develop effective …

The blood-brain barrier (BBB) poses a major challenge for developing effective antibody
therapies for neurological diseases. Using transcriptomic and proteomic profiling, we …

Pharmacokinetic evaluation is an essential component of drug discovery and should be
conducted early in the process so that those compounds with the best chance of success are …

When analyzing pharmacokinetic data, one generally employs either model fitting using
nonlinear regression analysis or non-compartmental analysis techniques (NCA). The …

Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune
gamma globulin (IgG) from elimination, the influence of FcRn on the tissue distribution of IgG …

Purpose: The development of new cancer drugs is slow and costly. HIV protease inhibitors
are Food and Drug Administration approved for HIV patients. Because these drugs cause …

Brain metastases are a common cause of death in stage IV metastatic melanoma.
Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that …

Interindividual variability in paclitaxel and docetaxel pharmacokinetics, toxicity and response
is extensive, and largely unexplained. We hypothesized that this is due to affinity of taxanes …

ATP-binding cassette transporters P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP) have been shown to work in concert to restrict brain penetration of several …